next is 2c, page-2

Annual loss reduced to $448,000 in FY13 from $1.9
million loss in FY12.

$4.5 million revenue

Cash balance $1.63 million and debt free.

At the moment Merck literally can not get enough of ANO's Alusion nanotechnology - ANO's revenues are guaranteed to increase as soon as they upgrade their production facility so they are able to sell the level of Alusion that Merck wants and needs to satisfy its own client base.

See the below excerpt from the annual report, particularly the 3rd sentence.

"Priorities for FY14:

Achieving above break-even financial performance, at a minimum.

Expanding ZinClear-IM® and ZinClear-XPTM into overseas markets, with a specific focus on Asia.

Increasing the capacity of our manufacturing facilities
to meet the requirements of the new Merck supply
agreement."

I can see some big dollars pouring into ANO pretty soon, hopefully Friday's price % jump put it on to a few more investor radars.